규제 업데이트

Lawmaker Jeon Jong-deok and the Korean Confederation of Trade Unions condemned the lack of budget for care‑worker pay and urged the National Assembly to allocate more funds.

MFDS approves Latica Eye Drops 5% for adult dry‑eye patients, marking Korea’s 44th domestically developed new drug and expanding treatment options.

The National Health Insurance Labor Union criticized the government's decision to keep the 2027 health insurance contribution rate unchanged, warning it could accelerate financial deterioration amid rising medical demand.

Ajou Pharmaceutical, together with G.L. PharmTech, secured MFDS approval for Latica Eye Drops 5% (recopolabone hydrate, code AJU‑S56), marking the company’s first marketed new drug and Korea’s 44th domestically developed new drug for dry eye.

Government promotion of the 실손24 electronic claim service has seen limited uptake, with only 13% of indemnity insurance holders enrolled as of July 2026.

The Ministry of Health and Welfare confirmed the 2027 health insurance premium rate will remain at 7.19% for both employee and regional subscribers, keeping the property premium score at 211.5 won.

The Korea Pharmaceutical Bio Association and the Ministry of Food and Drug Safety will host a technical training on parametric release for final sterilized product manufacturers on September 29 in Cheongju.

The National Assembly has filed two bills—one amending the Health‑Medical Technology Promotion Act and another proposing a regulatory sandbox—to accelerate validation and commercialization of new health‑care technologies.

The Ministry of Health and Welfare announced that a State Council‑approved amendment to the National Health Insurance Act now clearly defines reimbursable and non‑reimbursable drugs, while preserving protections for severe and rare disease patients.

The Cheongju City Pharmacists Association convened a meeting on Sep 7 to discuss recent regional pharmacy issues and challenges of non-face-to-face drug delivery, focusing on warehouse-type pharmacies.

HIRA has appointed Ajou University Prof. Park Rae‑woong, an expert in health data and AI, as the 9th Chair of its Clinical Review Committee for a two‑year term.

Professor Park Rae-woong of Ajou University, an expert in health data and AI, has been appointed as the new chair of the Health Insurance Review & Assessment Service's Clinical Review Committee for a two‑year term starting Sep 14, 2026.